Host-Directed Therapeutics as a Novel Approach for Tuberculosis Treatment

키워드

참고문헌 (68)

1. Zaman K., "Tuberculosis: a global health problem", J. Health Popul. Nutr, 28, pp.111~113 (2010)
2. Global Tuberculosis Report 2016, "World Health Organization", WHO, ~ (2016)
3. Schnippel K, "Costs of inpatient treatment for multidrug-resistant tuberculosis in South Africa", Trop. Med. Int. Health, 18, pp.109~116 (2013)
4. Arbex MA, "Antituberculosis drugs: drug interactions, adverse effects, and use in special situations. Part 1: first-line drugs", J. Bras. Pneumol, 36, pp.626~640 (2010)
5. Zumla A, "Inflammation and tuberculosis: host-directed therapies", J. Intern. Med, 277, pp.373~387 (2015)
6. Hawn TR, "Hostdirected therapeutics for tuberculosis: can we harness the host?", Microbiol. Mol. Biol. Rev, 77, pp.608~627 (2013)
7. Zumla A, "Towards host-directed therapies for tuberculosis", Nat. Rev. Drug Discov, 14, pp.511~512 (2015)
8. World health Organization, "Treatment of Tuberculosis: Guidelines", WHO, ~ (2010)
9. D’Ambrosio L, "New anti-tuberculosis drugs and regimens:2015 update", ERJ Open Res, 1 (2015)
10. Timmins GS, "Mechanisms of action of isoniazid", Mol. Microbiol, 62, pp.1220~1227 (2006)
11. Shi W, "Pyrazinamide inhibits trans-translation in Mycobacterium tuberculosis", Science, 333, pp.1630~1632 (2011)
12. Kim JJ, "Host cell autophagy activated by antibiotics is required for their effective antimycobacterial drug action", Cell Host Microbe, 11, pp.457~468 (2012)
13. Zullo AJ, "Old antibiotics target TB with a new trick", Cell Host Microbe, 11, pp.419~420 (2012)
14. Kolyva AS, "Old and New TB Drugs:Mechanisms of Action and Resistance" (2012), INTECH Open Access Publisher
15. Zumla A, "Advances in the development of new tuberculosis drugs and treatment regimens", Nat. Rev. Drug Discov, 12, pp.388~404 (2013)
16. Rattan A, "Multidrug-resistant Mycobacterium tuberculosis: molecular perspectives", Emerg. Infect. Dis, 4, pp.195~ (1998)
17. Lange C, "Management of patients with multidrug-resistant", extensively drug-resistant tuberculosis in Europe: a TBNET consensus statement, 2014, pp.44, 23~63
18. World health Organization, "Guidelin es for the Programmatic Management of Drug-resistant Tuberculosis - 2011 Update", WHO, ~ (2011)
19. Sharma D, "Mutational analysis of S12 protein and implications for the accuracy of decoding by the ribosome", J. Mol. Biol, 374, pp.1065~1076 (2007)
20. Crofton J, "Streptomycin resistance in pulmonary tuberculosis", Br. Med. J, 2, pp.1009~ (1948)
21. Rich M, "The PIH Guide to the Medical Management of Multidrug-resistant Tuberculosis" (2003), Partners in Health
22. Salian S, "Structure-activity relationships among the kanamycin aminoglycosides: role of ring I hydroxyl and amino groups", Antimicrob. Agents Chemother, 56, pp.6104~6108 (2012)
23. Arbex MA, "Antituberculosis drugs: drug interactions, adverse effects, and use in special situations. Part 2: second line drugs", J. Bras. Pneumol, 36, pp.641~656 (2010)
24. Aubry A, "Mycobacterium tuberculosis DNA gyrase: interaction with quinolones and correlation with antimycobacterial drug activity", Antimicrob. Agents Chemother, 48, pp.1281~1288 (2004)
25. Wade MM, "Mechanisms of drug resistance in Mycobacterium tuberculosis", Front. Biosci, 9, pp.975~994 (2004)
26. Das KM, "Adverse reactions during salicylazosulfapyridine therapy and the relation with drug metabolism and acetylator phenotype", N. Engl. J. Med, 289, pp.491~495 (1973)
27. Caceres NE, "Overexpression of the D-alanine racemase gene confers resistance to D-cycloserine in Mycobacterium smegmatis", J. Bacteriol, 179, pp.5046~5055 (1997)
28. Baulard AR, "Activation of the pro-drug ethionamide is regulated in mycobacteria", J. Biol. Chem, 275, pp.28326~28331 (2000)
29. Carette X, "Structural activation of the transcriptional repressor EthR from Mycobacterium tuberculosis by single amino acid change mimicking natural and synthetic ligands", Nucleic Acids Res, 40, pp.3018~3030 (2012)
30. Bouza E, "Linezolid: pharmacokinetic characteristics and clinical studies", Clin. Microbiol. Infect, 7(Suppl 4), pp.75~82 (2001)
31. Tato M, "In vitro activity of linezolid against Mycobacterium tuberculosis complex, including multidrug-resistant Mycobacterium bovis isolates", Int. J. Antimicrob. Agents, 28, pp.75~78 (2006)
32. Lee M, "Linezolid for treatment of chronic extensively drugresistant tuberculosis", N. Engl. J. Med, 367, pp.1508~1518 (2012)
33. Watkins RR, "An evidencebased review of linezolid for the treatment of methicillinresistant Staphylococcus aureus (MRSA): place in therapy", Core Evid, 7, pp.131~143 (2012)
34. Zumla A, "Potential of immunomodulatory agents as adjunct host-directed therapies for multidrug-resistant tuberculosis", BMC Med, 14, pp.89~ (2016)
35. Bento CF, "Autophagy in the fight against tuberculosis", DNA Cell Biol, 34, pp.228~242 (2015)
36. Hur KY, "New mechanisms of metformin action: focusing on mitochondria and the gut", J. Diabetes Investig, 6, pp.600~609 (2015)
37. Yang CS, "The AMPK-PPARGC1A pathway is required for antimicrobial host defense through activation of autophagy", Autophagy, 10, pp.785~802 (2014)
38. Singhal A, "Metformin as adjunct antituberculosis therapy", Sci. Transl. Med, 6 (2014)
39. Napier RJ, "Imatinib-sensitive tyrosine kinases regulate mycobacterial pathogenesis and represent therapeutic targets against tuberculosis", Cell Host Microbe, 10, pp.475~485 (2011)
40. Bruns H, "Abelson tyrosine kinase controls phagosomal acidification required for killing of Mycobacterium tuberculosis in human macrophages", J. Immunol, 189, pp.4069~4078 (2012)
41. Vilaplana C, "Ibuprofen therapy resulted in significantly decreased tissue bacillary loads and increased survival in a new murine experimental model of active tuberculosis", J. Infect. Dis, 208, pp.199~202 (2013)
42. Mayer-Barber KD, "Host-directed therapy of tuberculosis based on interleukin-1 and type I interferon crosstalk", Nature, 511, pp.99~103 (2014)
43. Chun RF, "Immunomodulation by vitamin D: implications for TB", Expert Rev. Clin. Pharmacol, 4, pp.583~591 (2011)
44. Mily A, "Significant effects of oral phenylbutyrate and vitamin D3 adjunctive therapy in pulmonary tuberculosis:a randomized controlled trial", PLoS One, 10, pp.e0138340~ (2015)
45. Singh A, "Inhibiting the programmed death 1 pathway rescues Mycobacterium tuberculosis-specific interferon gamma-producing T cells from apoptosis in patients with pulmonary tuberculosis", J. Infect. Dis, 208, pp.603~615 (2013)
46. Grosso JF, "CTLA-4 blockade in tumor models: an overview of preclinical and translational research", Cancer Immun, 13, pp.5~ (2013)
47. Rivero-Lezcano OM., "Cytokines as immunomodulators in tuberculosis therapy", Recent Pat. Antiinfect. Drug Discov, 3, pp.168~176 (2008)
48. Ottenhoff TH, "Control of human host immunity to mycobacteria", Tuberculosis, 85, pp.53~64 (2005)
49. Denis M, "Granulocyte-macrophage colonystimulating factor restricts growth of tubercle bacilli in human macrophages", Immunol. Lett, 24, pp.203~206 (1990)
50. Chroneos ZC, "Immunoregulatory Role of GM-CSF in Pulmonary Tuberculosis" (2012), INTECH Open Access Publisher
51. Nelson BH., "IL-2, regulatory T cells, and tolerance", J. Immunol, 172, pp.3983~3988 (2004)
52. Johnson BJ, "Clinical and immune responses of tuberculosis patients treated with low-dose IL-2 and multidrug therapy", Cytokines Mol. Ther, 1, pp.185~196 (1995)
53. Johnson BJ, "rhuIL-2 adjunctive therapy in multidrug resistant tuberculosis: a comparison of two treatment regimens and placebo", Tuber. Lung Dis, 78, pp.195~203 (1997)
54. Wallis RS, "Adalimumab treatment of life-threatening tuberculosis", Clin. Infect. Dis, 48, pp.1429~1432 (2009)
55. Rossi JF, "Interleukin-6 as a therapeutic target", Clin. Cancer Res, 21, pp.1248~1257 (2015)
56. Okada M, "Anti-IL-6 receptor antibody causes less promotion of tuberculosis infection than anti-TNF-alpha antibody in mice", Clin. Dev. Immunol, 2011, pp.404929~ (2011)
57. Datta M, "Anti-vascular endothelial growth factor treatment normalizes tuberculosis granuloma vasculature and improves small molecule delivery", Proc. Natl. Acad. Sci. USA, 112, pp.1827~1832 (2015)
58. Zumla A, "Host-directed therapies for infectious diseases: current status, recent progress, and future prospects", Lancet Infect. Dis, 16, pp.e47~e63 (2016)
59. Biswajit Podder, "Ursolic Acid Activates Intracellular Killing Effect of Macrophages During Mycobacterium tuberculosis Infection", Journal of Microbiology and Biotechnology, 25(5), pp.738~744 (2015), 한국미생물·생명공학회[DOI]
60. Susana Flores-Villalva, "What Can Proteomics Tell Us about Tuberculosis?", Journal of Microbiology and Biotechnology, 25(8), pp.1181~1194 (2015), 한국미생물·생명공학회[DOI]
61. Tiwari B, "An immunomodulatory role for the Mycobacterium tuberculosis region of difference 1locus proteins PE35 (Rv3872) and PPE68 (Rv3873)", FEBS J, 281, pp.1556~1570 (2014)
62. Yang CS, "Toxoplasma gondii GRA7-induced TRAF6 activation contributes to host protective immunity", Infect. Immun, 84, pp.339~350 (2015)
63. Koh HJ, "Toxoplasma gondii GRA7-targeted ASC and PLD1 promote antibacterial host defense via PKCalpha", PLoS Pathog, 13, pp.e1006126~ (2017)
64. Pedral-Sampaio DB, "Use of Rhu-GM-CSF in pulmonary tuberculosis patients: results of a randomized clinical trial", Braz. J. Infect. Dis, 7, pp.245~252 (2003)
65. Wallis RS., "Reconsidering adjuvant immunotherapy for tuberculosis", Clin. Infect. Dis, 41, pp.201~208 (2005)
66. Phillips BL, "LAG3 expression in active Mycobacterium tuberculosis infections", Am. J. Pathol, 185, pp.820~833 (2015)
67. Postow MA, "Immune checkpoint blockade in cancer therapy", J. Clin. Oncol, 33, pp.1974~1982 (2015)
68. Parida SK, "Cellular therapy in tuberculosis", Int. J. Infect. Dis, 32, pp.32~38 (2015)

관련 논문AI추천